Settlement of dispute

RNS Number:2938R
BTG PLC
24 October 2003

24 October 2003


                BTG plc: Settlement of dispute with Acambis plc


BTG plc (LSE: BGC), the global technology commercialisation company, today
announced the settlement of a legal dispute with Acambis plc, relating to BTG's
entitlement to 2% of Acambis's turnover.  Acambis has agreed to pay to BTG #12
million in full and final settlement of its current and future obligations.


Ian Harvey, Chief Executive Officer of BTG, said: "We are very pleased with the
terms of this settlement, which we believe are fair to both parties.  This gives
us a guaranteed #12 million and removes the potential for ongoing uncertainty."


The dispute related to an agreement signed in 1997 between BTG and Peptide
Therapeutics (now Acambis).  BTG assigned certain technology in return for a
royalty or an entitlement to 2% of Peptide Group's turnover going forward, and
an equity stake.  Under the original agreement, BTG would have received #1.6
million from Acambis in the year ended 31 March 2003 in respect of turnover
generated by Acambis up to that date.  The balance represents payments in
relation to turnover to be generated by Acambis in the future.


                                      Ends


For further information contact:


BTG                                                         Financial Dynamics

Andy Burrows, Director of Investor Relations                Ben Atwell

[phone]                                         [phone]


About BTG

BTG finds, develops and commercialises emerging technologies in the life and
physical sciences. These innovations are protected by a strong portfolio of
intellectual property that BTG develops and enhances. BTG then captures the
value in these technologies through licensing and venturing activities. From the
origins of its business in 1949, BTG has commercialised major innovations such
as Magnetic Resonance Imaging (MRI), recombinant factor IX blood-clotting
protein, Campath(R) (alemtuzumab) and Multilevel Cell (MLC) memory. BTG is
quoted on the London Stock Exchange under the symbol "BGC" and operates from
offices in London and Philadelphia, with representation in Tokyo. BTG operates
through wholly owned subsidiaries, BTG International Ltd. and BTG International
Inc. in the UK and USA, respectively. Further information on BTG can be found at
www.btgplc.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCPUGQPUUPWGWC